





Biosafety Clearing-House (BCH)

IRD NATIONAL REPORT ON THE IMPLEMENTATION OF THE CARTAGENA OTOCOL ON BIOSAFETY (NR3)	BCH-NR3-ME-115704
General Information	T UPDATED: 03 SEP 202
Country	
Montenegro PARTY TO THE CARTAGENA PROTOCOL ON BIOSAFETY ENTRY INTO F	ORCE: 03 JUN 2006
9. Organizations/stakeholders who were consulted or participated in the preparation of th	nis report
Administration for Food Safety, Veterinary and Phytosanitary Affairs Ministration Agriculture and Rural Development Biotechnical Faculty, University of Mon	- HN
10. Time period covered by this report From	
01 Jan 2011	
Γο	
31 Dec 2015	
Party to the Cartagena Protocol on Biosafety 11. Is your country a Party to the Cartagena Protocol on Biosafety (CPB)?	
Yes	EN
Article 2 - General provisions	
14. Has your country introduced the necessary legal, administrative and other measure implementation of the Protocol?	es for the
A domestic regulatory framework is partially in place	EN
15. If you indicated that a national biosafety framework exists in the above question, w operational?	hen did it become
2008	EN

16. Which specific instruments are in place for the implementation of your national biosafety framework?

One or more national biosafety laws

17. Has your country established a mechanism for the budgetary allocations of funds for the operation of its national biosafety framework?

Yes, to some extent

Additional Information

In the annual program of Phytosanitary measures, each year a component, dedicated to control of seed and planting material on GMO is included, with funds allocated for this purpose from Budget of Montenegro.

18. Does your country have permanent staff to administer functions directly related to the national biosafety framework?

No

19. If you answered Yes to question 18, how many permanent staff members are in place whose functions are directly related to the national biosafety framework?

20. Has your country's biosafety framework / laws / regulations / guidelines been submitted to the Biosafety Clearing-House (BCH)?

Partially

21. Here you may provide further details on the implementation of Article 2 in your country

Law on GMO (OG of MNE no 22/2008). This is the umbrella law for GMO.

ΕN

EN

EN

EN

Article 5 - Pharmaceuticals

22. Does your country regulate the transboundary movement, handling and use of living modified organisms (LMOs) which are pharmaceuticals?

Yes, to some extent

Additional Information

In the Law on Medicines (OG of MNE no 56/2011) a section dedicated to EXAMINATION OF MEDICINES TO PROVIDE DOCUMENTATION IN THE PROCESS OF AUTHORIZATION OF THE MEDICINAL PRODUCT, paragraph 72 states the following:The (drug and medical agency) Agency shall issue a clinical trial authorization within 60 days of receipt of a complete application with documentation.
br />The period for granting the permit ΕN

EN

referred to in paragraph 1 of this Article may be extended by a maximum of 30 days, or a total of 90 days, if the clinical trials refer to drugs for gene therapy or somatic cell therapy or to medicines containing genetically modified organisms. 23. If you answered Yes to question 22, has this information been submitted to the BCH? Yes EN 24. Here you may provide further details on the implementation of Article 5 in your country: Article 6 - Transit and Contained use 25. Does your country regulate the transit of LMOs? ΕN Yes 26. Does your country regulate the contained use of LMOs? ΕN Yes 27. If you answered Yes to questions 25 or 26, has this information been submitted to the BCH? ΕN Yes 28. Here you may provide further details on the implementation of Article 6 in your country: Articles 7 to 10 - Advance Informed Agreement (AIA) and intentional introduction of LMOs into the environment 29. Has your country adopted law(s) / regulations / administrative measures for the operation of the AIA procedure of the Protocol OR a domestic regulatory framework consistent with the Protocol regarding the transboundary movement of LMOs for intentional introduction into the environment? Yes EN 30. Has your country established a mechanism for taking decisions regarding first intentional transboundary movements of LMOs for intentional introduction into the environment? EN No 31. If you answered Yes to question 30, does the mechanism also apply to cases of intentional introduction

of LMOs into the environment that were not subject to transboundary movement?

32. Has your country established legal requirements for exporters under its jurisdiction to notify in writing the competent national authority of the Party of import prior to the intentional transboundary movement of an LMO that falls within the scope of the AIA procedure? No EN 33. Has your country established legal requirements for the accuracy of information contained in the notification? ΕN Yes 34. Has your country ever received an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment? No ΕN 35. Has your country ever taken a decision on an application / notification regarding intentional transboundary movements of LMOs for intentional introduction into the environment? EN No 36. If you answered Yes to question 35, how many LMOs has your country approved to date for import for intentional introduction into the environment? 37. If you answered Yes to question 35, how many LMOs, not imported, has your country approved to date for intentional introduction into the environment? 38. In the current reporting period, how many applications/notifications has your country received regarding intentional transboundary movements of LMOs for intentional introduction into the environment? ΕN None 39. In the current reporting period, how many decisions has your country taken regarding intentional transboundary movements of LMOs for intentional introduction into the environment? ΕN None

40. With reference to the decisions taken on intentional transboundary movements of LMOs for intentional introduction into the environment, has your country received a notification from the Party(ies) of export or from the exporter(s) prior to the transboundary movement?

41. Did the notifications contain complete information (at a minimum the information specified in Annex I of the Cartagena Protocol on Biosafety)?

42. Has your country acknowledged receipt of the notifications to the notifier within ninety days of receipt?

43. Has your country informed the notifier(s) and the BCH of its decision(s)?

44. What percentage of your country's decisions fall into the following categories?

45. In cases where your country approved an import with conditions or prohibited an import, did it provide reasons on which its decisions were based to the notifier and the BCH?

46. Here you may provide further details on the implementation of Articles 7-10 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs for intentional introduction to the environment

Article 11 - Procedure for living modified organisms intended for direct use as food or feed, or for processing (LMOs-FFP)

47. Has your country adopted specific law(s) or regulation(s) for decision-making regarding domestic use, including placing on the market, of LMOs-FFP?

EN

ΕN

ΕN

EN

EN

Yes

48. Has your country established legal requirements for the accuracy of information to be provided by the applicant?

Yes

49. Has your country established a mechanism to ensure that decisions regarding LMOs-FFP that may be subject to transboundary movement will be communicated to the Parties through the BCH?

Yes

50. Has your country established a mechanism for taking decisions on the import of LMOs-FFP?

Yes

51. Has your country indicated its needs for financial and technical assistance and capacity-building in respect of LMOs-FFP?

No

52. Has your country ever taken a decision on LMOs-FFP (either on import or domestic use)?

53. How many LMOs-FFP has your country approved to date?

54. In the current reporting period, how many decisions has your country taken regarding the import of LMOs-FFP?

55. In the current reporting period, how many decisions has your country taken regarding domestic use, including placing on the market, of LMOs-FFP?

56. Has your country informed the Parties through the BCH of its decision(s) regarding import, of LMOs-FFP?

57. Has your country informed the Parties through the BCH of its decision(s) regarding domestic use, including placing on the market, of LMOs-FFP within 15 days?

58. Here you may provide further details on the implementation of Article 11 in your country, including measures in case of lack of scientific certainty on potential adverse effects of LMOs-FFP

Article 12 - Review of decision

59. Has your country established a mechanism for the review and change of a decision regarding an intentional transboundary movement of LMOs?

No

60. Has your country ever received a request for a review of a decision?

No

61. Has your country ever reviewed / changed a decision regarding an intentional transboundary movement of LMOs?

No

62. In the current reporting period, how many decisions were reviewed and/or changed regarding an intentional transboundary movement of an LMO?

None

63. Has your country informed both the notifier and the BCH of the review and/or changes in the decision?

ΕN

ΕN

ΕN

EN

64. Has your country informed both the notifier and the BCH of the review and changes in the decision within thirty days?

65. Has your country provided reasons to both the notifier and the BCH for the review and/or changes in the decision?

66. Here you may provide further details on the implementation of Article 12 in your country

Article 13 - Simplified procedure

67. Has your country established a system for the application of the simplified procedure regarding an intentional transboundary movement of LMOs?

No

68. Has your country ever applied the simplified procedure?

No

69. If you answered Yes to question 68, has your country informed the Parties through the BCH of the cases where the simplified procedure applies?

70. In the current reporting period, how many LMOs has your country applied the simplified procedure to?

None

71. Here you may provide further details on the implementation of Article 13 in your country

Article 14 - Bilateral, regional and multilateral agreements and arrangements

72. Has your country entered into any bilateral, regional or multilateral agreements or arrangements?

No

73. If you answered Yes to question 72, how many LMO-related collaborative bilateral/multilateral arrangements has your country established with other Parties/non-Parties?

74. If you answered Yes to question 72, has your country informed the Parties through the BCH of the agreements or arrangements?

75. If you answered Yes to question 72, please provide a brief description of the scope and objective of the agreements or arrangements entered into

EN

EN

ΕN

ΕN

76. Here you may provide further details on the implementation of Article 14 in your country

Articles 15 & 16 - Risk Assessment and Risk Management

77. Has your country established a national framework for conducting risk assessments prior to taking decisions regarding LMOs?

ΕN

EN

ΕN

ΕN

EN

EN

EN

Yes

78. If you answered Yes to question 77, does this framework include procedures for identifying and/or training national experts to conduct risk assessments?

79 a. How many people in your country have been trained in risk assessment, monitoring, management and control of LMOs? Risk assessment:

None

79 b. How many people in your country have been trained in risk assessment, monitoring, management and control of LMOs? Management / Control:

None

79 c. How many people in your country have been trained in risk assessment, monitoring, management and control of LMOs? Monitoring:

None

80. Is your country using training material and/or technical guidance for training in risk assessment and risk management of LMOs?

No

81. Is your country using the "ManualonRiskAssessmentofLMOs" (developed by CBD Secretariat) for training in risk assessment?

No

82. Is your country using the "GuidanceonRiskAssessmentofLMOs" (developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management) for training in risk assessment?

No

83. Are the currently available training materials or technical guidance on risk assessment and/or risk

management of LMOs sufficient?

n/a

84 a. Does your country have the capacity to detect, identify, assess and/or monitor living modified organisms or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health? Detect:

No

84 b. Does your country have the capacity to detect, identify, assess and/or monitor living modified organisms or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health? Identify:

No

84 c. Does your country have the capacity to detect, identify, assess and/or monitor living modified organisms or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health? Assess:

No

84 d. Does your country have the capacity to detect, identify, assess and/or monitor living modified organisms or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity, taking into account risks to human health? Monitor:

No

85 a. Has your country adopted or used any guidance documents for the purpose of conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers? Risk assessment:

No

85 b. Has your country adopted or used any guidance documents for the purpose of conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers? Risk management:

No

86. Is your country using the "GuidanceonRiskAssessmentofLMOs" (developed by the Online Forum and the AHTEG on Risk Assessment and Risk Management) for conducting risk assessment or risk management, or for evaluating risk assessment reports submitted by notifiers?

No

ΕN

EN

ΕN

EN

EN

ΕN

EN

ΕN

87. Has your country adopted any common approaches to risk assessment with other countries?

No

88. Has your country cooperated with other Parties with a view to identifying LMOs or specific traits that may have adverse effects on the conservation and sustainable use of biological diversity?

No

89. Has your country ever conducted a risk assessment of an LMO including any type of risk assessment of LMOs, e.g. for contained use, field trials, commercial purposes, direct use as food, feed, or for processing?

No

90. If you answered Yes to question 89, please indicate the scope of the risk assessments (select all that apply):

91. If you answered Yes to question 89, were the summary reports of the risk assessments submitted to the BCH?

92. If you answered Yes to question 89, were risk assessments conducted for all decisions taken on LMOs for intentional introduction into the environment or on domestic use of LMOs for direct use as food, feed, or for processing?

93. If you answered Yes to question 89, how many risk assessments were conducted in the current reporting period?

94. Has your country taken measures to ensure that any LMO, whether imported or locally developed, undergoes an appropriate period of observation that is commensurate with its life-cycle or generation time before it is put to its intended use?

No

95. Has your country established a mechanism for monitoring potential effects of LMOs that are released into the environment?

No

96. Does your country have the infrastructure (e.g. laboratory facilities) for monitoring or managing LMOs?

No

ΕN

EN

ΕN

ΕN

ΕN

ΕN

97. Here you may provide further details on the implementation of Articles 15 and 16 in your country

We never received request for approval of LMO, GMO.

ΕN

Article 17 - Unintentional transboundary movements and emergency measures 98. Has your country established and maintained appropriate measures to prevent unintentional transboundary movements of LMOs? EN Yes, to some extent Additional Information ΕN Legislation is in place 99. Has your country established a mechanism for addressing emergency measures in case of unintentional transboundary movements of LMOs that are likely to have significant adverse effect on biological diversity? No ΕN 100. Does your country have the capacity to take appropriate measures in the event that an LMO is unintentionally released? ΕN No 101. In the current reporting period, how many times has your country received information concerning occurrences that led, or may have led, to unintentional transboundary movement(s) of one or more LMOs to or from territories under its jurisdiction? ΕN Never 102. If you answered Yes to question 101, has your country notified affected or potentially affected States, the BCH and, where appropriate, relevant international organizations, of the above release? 103. If you answered Yes to question 101, who did your country notify? 104. If you answered Yes to question 101, has your country immediately consulted the affected or potentially affected States to enable them to determine appropriate responses and initiate necessary action, including emergency measures? 105. Here you may provide further details on the implementation of Article 17 in your country Article 18 - Handling, transport, packaging and identification

106. Has your country taken measures to require that LMOs that are subject to transboundary movement are handled, packaged and transported under conditions of safety, taking into account relevant international rules and standards?

Yes

107. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is not known through means such as identity preservation systems, they may contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?

No

108. Has your country taken measures to require that documentation accompanying LMOs-FFP clearly identifies that, in cases where the identity of the LMOs is known through means such as identity preservation systems, they contain living modified organisms and are not intended for intentional introduction into the environment, as well as a contact point for further information?

No

109. If you answered Yes or Yes, to some extent to question(s) 107 and/or 108, what type of documentation does your country require for the identification of LMOs-FFP?

110. Has your country taken measures to require that documentation accompanying LMOs that are destined for contained use clearly identifies them as living modified organisms and specifies any requirements for the safe handling, storage, transport and use, the contact point for further information, including the name and address of the individual and institution to whom the LMO are consigned?

No

111. If you answered Yes or Yes, to some extent to question 110, what type of documentation does your country require for the identification of LMOs that are destined for contained?

112. Has your country taken measures to require that documentation accompanying LMOs that are intended for intentional introduction into the environment of the Party of import, clearly identifies them as living modified organisms; specifies the identity and relevant traits and/or characteristics, any requirements for the safe handling, storage, transport and use, the contact point for further information and, as appropriate, the name and address of the importer and exporter; and contains a declaration that the movement is in conformity with the requirements of this Protocol applicable to the exporter?

No

ΕN

ΕN

EN

EN

EN

113. If you answered Yes or Yes, to some extent to question 112, what type of documentation does your country require for the identification of LMOs that are intended for intentional introduction into the environment?

114. Does your country have available any guidance for the purpose of ensuring the safe handling, transport, and packaging of living modified organisms?				
No	EN			
115. Does your country have the capacity to enforce the requirements of identification and docume of LMOs?				
Yes	EN			
116. How many customs officers in your country have received training in the identification of LMOs?				
None	EN			
117. Has your country established procedures for the sampling and detection of LMOs?				
Yes	EN			
118. How many laboratory personnel in your country have received training in detection of LMOs?				
None	EN			
119. Does your country have reliable access to laboratory facilities for the detection of LMOs?				
Yes	EN			
120. How many laboratories in your country are certified for LMO detection?				
None	EN			
121. How many of the certified laboratories in the previous question are currently operating in the detection of LMOs?				
122. Here you may provide further details on the implementation of Article 18 in your country:				
We do not have laboratory, but we are sending samples to the authorized laboratory in Cratia.	EN			
Article 19 - Competent National Authorities and National Focal Points				

123. In case your country has designated more than one competent national authority, has your country established a mechanism for the coordination of their actions prior to taking decisions regarding LMOs?

No

124. Has your country established adequate institutional capacity to enable the competent national authority(ies) to perform the administrative functions required by the Cartagena Protocol on Biosafety?

No

125. Here you may provide further details on the implementation of Article 19 in your country

Article 20 - Information Sharing and the Biosafety Clearing-House (BCH)

126 a. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Existing national legislation, regulations and guidelines for implementing the Protocol, as well as information required by Parties for the advance informed agreement procedure (Article 20, paragraph 3 (a))

Information available and in the BCH

126 b. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. National laws, regulations and guidelines applicable to the import of LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 5)

Information available and in the BCH

126 c. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Bilateral, multilateral and regional agreements and arrangements (Articles 14, paragraph 2 and 20, paragraph 3 (b))

Information not available

126 d. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Contact details for competent national authorities (Article 19, paragraphs 2 and 3), national focal points (Article 19, paragraphs 1 and 3), and emergency contacts (Article 17, paragraph 3 (e))

Information available and in the BCH

126 e. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been

ΕN

ΕN

ΕN

ΕN

EN

submitted to the BCH. Reports submitted by the Parties on the operation of the Protocol (Article 20, paragraph 3 (e))

Information not available

126 f. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Decisions by a Party on regulating the transit of specific living modified organisms (LMOs) (Article 6, paragraph 1)

Information not available

126 g. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Occurrence of unintentional transboundary movements that are likely to have significant adverse effects on biological diversity (Article 17, paragraph 1)

Information not available

126 h. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Illegal transboundary movements of LMOs (Article 25, paragraph 3)

Information not available

126 i. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Final decisions regarding the importation or release of LMOs (i.e. approval or prohibition, any conditions, requests for further information, extensions granted, reasons for decision) (Articles 10, paragraph 3 and 20, paragraph 3(d))

Information not available

126 j. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Information on the application of domestic regulations to specific imports of LMOs (Article 14, paragraph 4)

Information not available

126 k. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Final decisions regarding the domestic use of LMOs that may be subject to transboundary movement for direct use as food or feed, or for processing (Article 11, paragraph 1)

ΕN

EN

ΕN

EN

EN

Information not available

126 I. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Final decisions regarding the import of LMOs intended for direct use as food or feed, or for processing that are taken under domestic regulatory frameworks (Article 11, paragraph 4) or in accordance with annex III (Article 11, paragraph 6) (requirement of Article 20, paragraph 3(d))

Information not available

126 m. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Declarations regarding the framework to be used for LMOs intended for direct use as food or feed, or for processing (Article 11, paragraph 6)

Information not available

126 n. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Review and change of decisions regarding intentional transboundary movements of LMOs (Article 12, paragraph 1)

Information not available

126 o. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. LMOs granted exemption status by each Party (Article 13, paragraph 1)

Information not available

126 p. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Cases where intentional transboundary movement may take place at the same time as the movement is notified to the Party of import (Article 13, paragraph 1)

Information not available

126 q. Please provide an overview of the status of the mandatory information provided by your country to the BCH by specifying for each category of information whether it is available and whether it has been submitted to the BCH. Summaries of risk assessments or environmental reviews of LMOs generated by regulatory processes and relevant information regarding products thereof (Article 20, paragraph 3 (c))

Information not available

EN

EN

ΕN

EN

ΕN

127. Has your country established a mechanism for strengthening the capacity of the BCH National Focal Point to perform its administrative functions?

EN

ΕN

ΕN

EN

ΕN

EN

ΕN

No

128. Has your country established a mechanism for the coordination among the BCH National Focal Point, the Cartagena Protocol focal point, and the competent national authority(ies) for making information available to the BCH?

Yes

129. Does your country use the information available in the BCH in its decision making processes on LMOs?

n/a

130. Has your country experienced difficulties accessing or using the BCH?

No

131. Is the information submitted by your country to the BCH complete and up-to date?

Yes

132. Please indicate the number of regional, national and international events organized in relation to biosafety (e.g. seminars, workshops, press conferences, educational events, etc.,) in the last 2 years:

None

133. Please indicate the number of biosafety related publications that has been made available in your country in the last year:

None

134. If biosafety related publications were made available (see question above), please indicate which modalities were preferred:

135. Here you may provide further details on the implementation of Article 20 in your country

Article 21 - Confidential information

136. Has your country established procedures to protect confidential information received under the Protocol?

137. Does your country allow the notifier to identify information that is to be treated as confidential?

Yes, always

138. Here you may provide further details on the implementation of Article 21 in your country

Article 22 - Capacity-building

139. Does your country have predictable and reliable funding for building capacity for the effective implementation of the Protocol?

No

140. Has your country received external support or benefited from collaborative activities with other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?

No

141. If you answered Yes to question 140, how were these resources made available?

142. Has your country provided support to other Parties in the development and/or strengthening of human resources and institutional capacities in biosafety?

No

143. If you answered Yes to question 142, how were these resources made available?

144. Has your country ever initiated a process to access GEF funds for building capacity in biosafety?

Yes

145. If you answered Yes to question 144, how would you characterize the process?

ΕN

EN

Difficult

146. Has your country ever received funding from the GEF for building capacity in biosafety?

Pilot Biosafety Enabling Activity

EN

ΕN

EN

147. During the current reporting period, has your country undertaken activities for the development and/ or strengthening of human resources and institutional capacities in biosafety? EN No 148. If you answered Yes to question 147, in which of the following areas were these activities undertaken? 149. During the current reporting period, has your country carried out a capacity-building needs assessment? No EN 150. If you answered Yes to question 149, has this information been submitted to the BCH? 151. Does your country still have capacity-building needs? ΕN Yes 152. If you answered Yes to question 151, indicate which of the following areas still need capacitybuilding. Institutional capacity Human resources capacity development and training Risk management Public awareness, participation and education in biosafety Information exchange and data management including participation in the Biosafety Clearing-House Scientific, technical and institutional collaboration at subregional, regional and international levels Identification of LMOs, including their detection Socio-economic considerations Implementation of the documentation requirements under Article 18.2 of the Protocol Measures to address unintentional and/or illegal transboundary movements of LMOs Scientific biosafety research relating to LMOs 153. Has your country developed a capacity-building strategy or action plan? ΕN No 154. Does your country have in place a functional national mechanism for coordinating biosafety capacitybuilding initiatives?

No

155. How many biosafety short-term training programmes and/or academic courses are offered annually in your country?

None

156. Has your country submitted the details of national biosafety experts to the Roster of Experts in the BCH?

No

157. Here you may provide further details on the implementation of Article 22 in your country, including further details about your experience in accessing GEF funds

Article 23 - Public awareness and participation

158. Has your country established a strategy or put in place legislation for promoting and facilitating public awareness, education and participation concerning the safe transfer, handling and use of LMOs?

No

159. Has your country designed and/or implemented an outreach/communication strategy on biosafety?

No

160. Does your country have any awareness and outreach programmes on biosafety?

No

161. If you answered Yes to question 160, please indicate what entity is responsible for carrying out the programmes and/or services and at which level the programmes take place (e.g. local, national, etc.):

162. Has your country established a biosafety website searchable archives, national resource centres or sections in existing national libraries dedicated to biosafety educational materials?

No

EN

EN

EN

ΕN

EN

ΕN

163. How many collaborative initiatives (including joint activities) on the Cartagena Protocol and other Conventions and processes has your government established in the last 4 years?

None

ΕN

164. Has your country established a mechanism to ensure public access to information on living modified organisms that may be imported?

No

165. Has your country es	stablished a mechanism to	consult the public in the	decision-making process
regarding LMOs?			

No

166. Has your country established a mechanism to make available to the public the results of decisions taken on LMOs?

No

167. Has your country informed the public about existing modalities for public participation in the decision-making process regarding living modified organisms?

No

168. If you answered Yes to question 167, please indicate the modalities used to inform the public:

169. If you indicated more than one modality for public participation in question 168, which one was most used?

170. Has your country taken any initiative to inform its public about the means of public access to the Biosafety Clearing-House?

No

171. How many academic institutions in your country are offering biosafety education and training courses and programmes?

None

172. Please indicate the number of educational materials and/or online modules on biosafety that are available and accessible to the public in your country:

None

173. In the current reporting period, has your country promoted and facilitated public awareness, education and participation concerning the safe transfer, handling and use of LMOs?

No

ΕN

ΕN

ΕN

ΕN

EN

EN

ΕN

ΕN

174. If you answered Yes to question 173, has your country cooperated with other States and international

bodies?

175. In the current reporting period, how many times has your country consulted the public in the decision-making process regarding LMOs and made the results of such decisions available to the public?

Never

176. Here you may provide further details on the implementation of Article 23 in your country

Article 24 - Non-Parties

177. Has your country entered into any bilateral, regional, or multilateral agreement with non-Parties regarding transboundary movements of LMOs?

No

178. Has your country ever imported LMOs from a non-Party?

No

179. Has your country ever exported LMOs to a non-Party?

No

180. If you answered Yes to questions 178 or 179, were the transboundary movements of LMOs consistent with the objective of the Cartagena Protocol on Biosafety?

181. If you answered Yes to questions 178 or 179, was information about these transboundary movements submitted to the BCH?

182. If your country is not a Party to the Cartagena Protocol, has it contributed information to the BCH on LMOs released in, or moved into, or out of, areas within its national jurisdiction?

183. Here you may provide further details on the implementation of Article 24 in your country:

Article 25 - Illegal transboundary movements

184. Has your country adopted domestic measures aimed at preventing and/or penalizing transboundary movements of LMOs carried out in contravention of its domestic measures to implement this Protocol?

Yes

ΕN

ΕN

ΕN

ΕN

185. Has your country established a strategy for detecting illegal transboundary movements of LMOs?

No

186. In the current reporting period, how many times has your country received information concerning cases of illegal transboundary movements of an LMO to or from territories under its jurisdiction?

Never

187. If your country received information concerning cases of illegal transboundary movements of an LMO in the current reporting period, has your country informed the BCH and the other Party(ies) involved?

188. If your country received information concerning cases of illegal transboundary movements of an LMO in the current reporting period, has your country established the origin of the LMO(s)?

189. If your country received information concerning cases of illegal transboundary movements of an LMO in the current reporting period, has your country established the nature of the LMO(s)?

190. If your country received information concerning cases of illegal transboundary movements of an LMO in the current reporting period, has your country established the circumstances of the illegal transboundary movement(s)?

191. Here you may provide further details on the implementation of Article 25 in your country

Article 26 - Socio-economic considerations

192. Does your country have any specific approaches or requirements that facilitate how socio-economic considerations should be taken into account in LMO decision making?

No

193. If your country has taken a decision on import, has it ever taken into account socio-economic considerations arising from the impact of the LMO on the conservation and sustainable use of biological diversity?

Not applicable

194. How many peer-reviewed published materials has your country used for the purpose of elaborating or determining national actions with regard to socio-economic considerations?

None

195. What is your country's experience, if any, in taking socio-economic considerations into account in

ΕN

EN

ΕN

EN

LMO decision making? Please give details:

196. Has your country cooperated with other Parties on research and information exchange on any socioeconomic impacts of LMOs?

ΕN

ΕN

ΕN

ΕN

EN

No

197. Here you may provide further details on the implementation of Article 26 in your country

Article 27 - Liability and Redress

198. Has your country ratified or acceded to the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress?

Yes

199. If you answered No to question 198, is there any national process in place towards becoming a Party?

200. Has your country received any financial and/or technical assistance for capacity-building in the area of liability and redress relating to living modified organisms?

No

201. Does your country have administrative or legal instrument that provide for response measures for damage to biodiversity resulting from living modified organisms?

No

202. Here you may provide further details on any activities undertaken in your country towards the implementation of the Nagoya-Kuala Lumpur Supplementary Protocol on Liability and Redress

Article 28 - Financial Mechanism and Resources

203. How much additional funding (in the equivalent of US dollars) has your country mobilized in the last four years to support implementation of the Biosafety Protocol, beyond the regular national budgetary allocation?

n/a

Article 33 - Monitoring and reporting

204 a. Does your country have in place a monitoring and/or an enforcement system for the

implementation of the Cartagena Protocol? Monitoring system:

No

204 b. Does your country have in place a monitoring and/or an enforcement system for the implementation of the Cartagena Protocol? Enforcement system:

ΕN

ΕN

ΕN

No

205. Has your country submitted all the previous due National Reports?

No

206. If you answered No to question 205, indicate the main challenges that hindered the submission:

5B6177DD-5E5E-434E-8CB7-D63D67D5EBED (the transfer of contact point was done in october 2019, and I do not have information why reports were not submitted)

Other information

207. Please use this field to provide any other information on issues related to national implementation of the Protocol, including any obstacles or impediments encountered.

Comments on reporting format

208. Please use this field to provide any other information on difficulties that you have encountered in filling in this report

BCH-NR3-ME-115704-1

Further Information

Questions about the Cartagena Protocol on Biosafety or the operation of the Biosafety Clearing-House may be directed to the Secretariat of the Convention on Biological Diversity. Secretariat of the Convention on Biological Diversity 413 rue Saint-Jacques, suite 800 Montreal, Québec, H2Y 1N9 Canada Fax: +1 514 288-6588 Email: secretariat@cbd.int